SymBio Pharmaceuticals Limited Profit Margin

SymBio Pharmaceuticals Limited (SYMQY) currently reports a profit margin of -576.8% as of September 2026. That compares with -298.95% in the prior-year period — down 92.9% year over year. That is below the sector sector average of 13.23%. Use the charts on this page to explore SymBio Pharmaceuticals Limited's profit margin history and peer comparisons.

SymBio Pharmaceuticals Limited's profit margin decreased from -298.95% to -576.8% — a 92.9% year-over-year decrease (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

SymBio Pharmaceuticals Limited's profit margin of -576.8% is lower than the its sector sector average of 13.23%. That is roughly 4461.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but SymBio Pharmaceuticals Limited's current -576.8% should be judged against industry norms (sector average: 13.23%) and against SYMQY's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -576.8%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 13.23%. From there, open related valuation or income-statement pages for SymBio Pharmaceuticals Limited, and consider following SYMQY for alerts when major investors trade the stock.